Total Payments
$2,758
2024 Payments
$487.57
Companies
17
Transactions
115
Medicare Patients
11,463
Medicare Billing
$10.0M
Payment Breakdown by Category
Food & Beverage$2,758 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,758 | 115 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $538.55 | 14 | $0 (2021) |
| ABBVIE INC. | $474.00 | 17 | $0 (2024) |
| Genentech USA, Inc. | $468.39 | 27 | $0 (2024) |
| Mallinckrodt LLC | $233.47 | 14 | $0 (2018) |
| Allergan, Inc. | $185.17 | 9 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $170.56 | 8 | $0 (2024) |
| Alcon Vision LLC | $147.48 | 2 | $0 (2022) |
| Alimera Sciences, Inc. | $112.49 | 6 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $108.64 | 5 | $0 (2024) |
| Astellas Pharma US Inc | $87.51 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $487.57 | 22 | ABBVIE INC. ($193.20) |
| 2023 | $398.61 | 16 | ABBVIE INC. ($124.88) |
| 2022 | $313.35 | 14 | Alcon Vision LLC ($105.98) |
| 2021 | $304.83 | 14 | Allergan, Inc. ($114.83) |
| 2020 | $149.05 | 9 | Novartis Pharmaceuticals Corporation ($89.45) |
| 2019 | $392.49 | 11 | Novartis Pharmaceuticals Corporation ($243.42) |
| 2018 | $169.94 | 8 | Mallinckrodt LLC ($95.64) |
| 2017 | $542.18 | 21 | Mallinckrodt LLC ($137.83) |
All Payment Transactions
115 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: EYE CARE | ||||||
| 12/11/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: Ophthalmology | ||||||
| 12/02/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/30/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/18/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $7.99 | General |
| Category: EYE CARE | ||||||
| 10/04/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: EYE CARE | ||||||
| 09/30/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Ophthalmology | ||||||
| 09/06/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $23.34 | General |
| 09/04/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $29.16 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/26/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 06/26/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: EYE CARE | ||||||
| 06/10/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $3.55 | General |
| Category: EYE CARE | ||||||
| 06/05/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: Ophthalmology | ||||||
| 05/28/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: Ophthalmology | ||||||
| 05/22/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: EYE CARE | ||||||
| 05/22/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.81 | General |
| Category: EYE CARE | ||||||
| 04/30/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: EYE CARE | ||||||
| 04/02/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Immunology and Ophthalmology | ||||||
| 02/21/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 02/16/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/13/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/09/2023 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $24.37 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/03/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $32.09 | General |
| 11/02/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $31.67 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 3,463 | 84,062 | $11.5M | $3.8M |
| 2022 | 22 | 2,982 | 21,926 | $6.4M | $2.6M |
| 2021 | 21 | 2,722 | 8,910 | $4.7M | $2.1M |
| 2020 | 22 | 2,296 | 6,711 | $3.1M | $1.4M |
Total Patients
11,463
Total Services
121,609
Medicare Billing
$10.0M
Procedure Codes
86
All Medicare Procedures & Services
86 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 224 | 74,160 | $6.1M | $2.1M | 35.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 91 | 770 | $1.3M | $522,872 | 39.9% |
| J3490 | Unclassified drugs | Office | 2023 | 64 | 228 | $2.2M | $404,115 | 18.7% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 63 | 1,935 | $1.0M | $232,898 | 23.1% |
| 67028 | Injection of drug into eye | Office | 2023 | 381 | 1,582 | $251,493 | $157,512 | 62.6% |
| 92134 | Imaging of retina | Office | 2023 | 891 | 2,481 | $108,188 | $72,638 | 67.1% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 17 | 396 | $262,152 | $70,687 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 457 | 726 | $97,315 | $67,105 | 69.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 596 | 886 | $85,063 | $53,315 | 62.7% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 21 | 161 | $53,935 | $25,482 | 47.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 212 | 212 | $38,030 | $23,512 | 61.8% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 24 | 26 | $23,929 | $16,327 | 68.2% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 15 | 16 | $18,759 | $13,621 | 72.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 131 | 139 | $20,350 | $13,390 | 65.8% |
| 67210 | Destruction of growth of retina using a laser | Office | 2023 | 16 | 17 | $10,514 | $6,599 | 62.8% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 36 | 86 | $10,750 | $5,831 | 54.2% |
| 92250 | Photography of the retina | Office | 2023 | 160 | 171 | $7,579 | $4,449 | 58.7% |
| 92242 | Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | Office | 2023 | 13 | 13 | $3,508 | $2,177 | 62.1% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 18 | 20 | $1,305 | $863.82 | 66.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 17 | 21 | $1,276 | $737.31 | 57.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 16 | 16 | $938.56 | $690.24 | 73.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 153 | 1,628 | $2.8M | $1.2M | 41.8% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 98 | 12,420 | $1.0M | $370,630 | 36.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 57 | 1,521 | $1.0M | $338,466 | 33.6% |
| J3590 | Unclassified biologics | Office | 2022 | 60 | 162 | $750,100 | $292,206 | 39.0% |
About Dr. Allan Hunter, MD
Dr. Allan Hunter, MD is a Ophthalmology healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1184748030.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Allan Hunter, MD has received a total of $2,758 in payments from pharmaceutical and medical device companies, with $487.57 received in 2024. These payments were reported across 115 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($2,758).
As a Medicare-enrolled provider, Hunter has provided services to 11,463 Medicare beneficiaries, totaling 121,609 services with total Medicare billing of $10.0M. Data is available for 4 years (2020–2023), covering 86 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Eugene, OR
- Active Since 03/18/2007
- Last Updated 04/19/2018
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1184748030
Products in Payments
- OZURDEX (Drug) $505.95
- BEOVU (Drug) $354.52
- Lucentis (Biological) $293.24
- ACTHAR (Biological) $233.47
- Vabysmo (Drug) $183.35
- EYLEA (Biological) $145.88
- Humira (Biological) $129.88
- Clareon (Device) $105.98
- Syfovre (Drug) $86.85
- YUTIQ (Drug) $76.02
- ILUVIEN (Drug) $63.87
- BROLUCIZUMAB (Drug) $42.67
- AcrySof (Device) $41.50
- PURIFIED CORTROPHIN GEL (Drug) $27.49
- EYLEA HD (Biological) $24.68
- VISUDYNE (Drug) $24.03
- XIPERE (Drug) $23.73
- Cimerli (Biological) $21.54
- VABYSMO (Drug) $15.95
- SUSVIMO (Drug) $14.81
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Eugene
Mr. Albert Edwards, Md, Phd, MD, PHD
Ophthalmology — Payments: $38,057
Ophthalmology $38,057
Dr. Robert Beardsley, M.d, M.D
Ophthalmology — Payments: $34,844
Ophthalmology $34,844
Blake Fausett, M.d, M.D
Ophthalmology — Payments: $27,666
Ophthalmology $27,666
Dr. Balamurali Ambati, Md, MD
Ophthalmology — Payments: $20,672
Ophthalmology $20,672
Dr. Joseph Mando, Md, MD
Ophthalmology — Payments: $7,362
Ophthalmology $7,362
Dr. Jason Gross, M.d, M.D
Ophthalmology — Payments: $6,389
Ophthalmology $6,389